ライフサイエンスコーパス: multidrug-resistant

1 Multidrug resistant A. baumannii has risen rapidly in Vi

2 In multivariate analysis, multidrug-resistant A. baumannii (odds ratio, 4.78; 95%

3 analyse the protein interaction network of a multidrug-resistant A. baumannii clinical strain (AB5075

4 ic agents used to treat infections caused by multidrug-resistant A. baumannii.

5 increased transmission risk; however, having multidrug-resistant-A. baumannii and specific healthcare

6 a potential selective advantage possessed by multidrug-resistant-A. baumannii in this environment and

7 n-resistant Staphylococcus aureus (MRSA) and multidrug-resistant Acinetobacter baumannii (MDR-AB) wer

8 Multidrug-resistant Acinetobacter baumannii presents a g

9 ion therapy is deployed for the treatment of multidrug-resistant Acinetobacter baumannii, as it can r

10 ycin-resistant enterococci, C difficile, and multidrug-resistant Acinetobacter.

11 y-onset infections; 66 isolates (50.0%) were multidrug resistant and, of 33 isolates tested for carba

12 The regimen could be effective against both multidrug-resistant and drug-susceptible tuberculosis in

13 Multidrug-resistant and epidemic strains are a large pro

14 ull gyrA and gyrB open reading frames in 240 multidrug-resistant and extensively drug-resistant tuber

15 utic options, particularly for patients with multidrug-resistant and extensively drug-resistant tuber

16 es in the world, and the increased number of multidrug-resistant and extremely drug-resistant strains

17 The global increase of multidrug-resistant and pan-resistant Acinetobacter isol

18 frequent cause of such infections, is often multidrug resistant, and chronically colonizes a sizable

19 s, we characterize l(2)03659 as a Drosophila multidrug resistant-associated ABC transporter.

20 transient hypoxia and the appearance of the multidrug resistant bacteria Staphylococcus simulans in

21 over new antibiotics or strategies to combat multidrug resistant bacteria, especially Gram-negative b

22 veterinary medicine causes the emergence of multidrug resistant bacteria.

23 Emerging multidrug-resistant bacteria are a challenge for modern

24 Multidrug-resistant bacteria are responsible for substan

25 The emergence of multidrug-resistant bacteria emphasizes the urgent need

26 The rapid emergence of multidrug-resistant bacteria has renewed interest in dev

27 to ameliorate the development and spread of multidrug-resistant bacteria in cirrhosis.

28 ion imbalance in living cells while fighting multidrug-resistant bacteria is a paramount topic.

29 Infections due to multidrug-resistant bacteria represent a major global he

30 ntions, including drugs and vaccines against multidrug-resistant bacteria such as Neisseria gonorrhoe

31 lator-associated pneumonia, and infection by multidrug-resistant bacteria were independently associat

32 With rapid emergence of multidrug-resistant bacteria, there is often a need to p

33 sesses potent antibacterial activity towards multidrug-resistant bacteria.

34 Multidrug resistant bacterial pathogens have become a se

35 quantum dots (QDs) can kill a wide range of multidrug-resistant bacterial clinical isolates, includi

36 Multidrug-resistant bacterial infections are an ever-gro

37 The incidence of multidrug-resistant bacterial infections is increasing g

38 min antibiotics are used clinically to treat multidrug-resistant bacterial infections, but their poor

39 , and have been proposed to be used to treat multidrug-resistant bacterial infections.

40 ed rational drug design approach to treating multidrug-resistant bacterial infections.

41 could serve as adjunctive treatments against multidrug-resistant bacterial infections.

42 The risk of infections caused by multidrug-resistant bacterial pathogens increases with h

43 chanism when combined with AgNPs against the multidrug-resistant bacterium Salmonella typhimurium DT

44 ith the industrial production of eggs and of multidrug-resistant, bloodstream-invasive infection in A

45 more active in vitro than paclitaxel in the multidrug resistant breast cancer cell line LCC6-MDR.

46 illus fumigatus and emerging threats such as multidrug resistant Candida auris are also alarming.

47 losis cases and the second highest number of multidrug resistant cases worldwide.

48 criminate isoniazid-monoresistant cases from multidrug-resistant cases within 2 days.

49 ream, or surgical site infection caused by a multidrug-resistant (cases) or -sensitive (controls) mic

50 mal-Pgp utilization enhances cytotoxicity to multidrug-resistant cells.

51 icrobial peptides displayed activity against multidrug-resistant clinical isolates of Escherichia col

52 le 9b and 9c were highly active also against multidrug-resistant clinical isolates.

53 Two different multidrug-resistant, clinical MRSA isolates were grown o

54 cterium tuberculosis CNCTC My 331/88 and six multidrug-resistant clinically isolated strains of M. tu

55 with accurate identification of the pandemic multidrug-resistant clonal subgroup ST131-H30.

56 of sequence type 131 (ST131) are a pandemic multidrug resistant clone associated with urinary tract

57 bial resistance was evaluated in an epidemic multidrug-resistant clone of K. pneumoniae (ST258).

58 e of serotype 35B disease and emergence of a multidrug-resistant clone reported in this issue of the

59 R genes associated with clinically important multidrug-resistant clones and epidemic plasmids, in Ame

60 The expansion of these multidrug-resistant clones suggests that the treatment o

61 especially with the emergence and spread of multidrug-resistant clones.

62 thin the outbreak (4.7%), including within a multidrug-resistant cluster that carried a rare rpoB mut

63 munity-based, commensal population underlies multidrug-resistant E. cloacae infections within hospita

64 tudy, we analysed a systematic collection of multidrug-resistant E. cloacae isolated between 2001 and

65 n testing of fosfomycin was performed on 649 multidrug-resistant E. coli clinical isolates collected

66 tion or induction of UhpT but are rare among multidrug-resistant E. coli clinical strains.

67 Preventing colonization by multidrug-resistant E. faecalis could therefore be a val

68 l envelope; these include metallopeptidases, multidrug-resistant efflux (MDR) pumps, TonB-dependent r

69 mycin has become a front-line antibiotic for multidrug-resistant Enterococcus faecium bloodstream inf

70 iotics reduced selective pressures favouring multidrug-resistant epidemic ribotypes and was associate

71 iotics reduced selective pressures favouring multidrug-resistant epidemic ribotypes and was associate

72 ly used antibiotics, with 18 % ESBL and 36 % multidrug resistant Escherichia coli strains.

73 A draft genome, annotated as multidrug resistant Escherichia coli, was retrieved from

74 As a result, multidrug-resistant, extensively drug-resistant, and pan

75 Candida auris is an emerging multidrug-resistant fungal pathogen causing nosocomial a

76 s in health care caused by the prevalence of multidrug resistant Gram-negative pathogens.

77 s using efflux pump inhibitors for combating multidrug resistant Gram-negative pathogens.

78 CI, 0.32-1.40), bacteriuria associated with multidrug-resistant gram-negative bacilli (9 vs 24 episo

79 r detection of known resistance genes in 108 multidrug-resistant Gram-negative bacilli.

80 efficacy of strategies for the prevention of multidrug-resistant gram-negative bacteria (MDR-GNB) in

81 olderia cepacia complex (Bcc) are a group of multidrug-resistant gram-negative bacteria rarely report

82 line of defence in serious infections due to multidrug-resistant Gram-negative bacteria, but their us

83 yse the cell, is the last-line treatment for multidrug-resistant Gram-negative infections.

84 he last-resort antibiotics used for treating multidrug-resistant Gram-negative pathogens.

85 valuated against panels of tetracycline- and multidrug-resistant Gram-positive and Gram-negative path

86 Acinetobacter pittii are a frequent cause of multidrug-resistant, healthcare-associated infections.

87 sub-Saharan Africa, and are associated with multidrug resistant HIV-1.

88 examined the evolutionary history of leading multidrug resistant hospital pathogens, the enterococci,

89 representative bacterial strains, including multidrug-resistant hospital isolates.

90 pe 258 (ST258) are among the most widespread multidrug-resistant hospital-acquired pathogens.

91 omial pneumonia, is a versatile and commonly multidrug-resistant human pathogen for which further ins

92 th or without reduced ejection fraction, and multidrug-resistant hypertension (RHT) are major worldwi

93 Multidrug-resistant infection was associated with prior

94 w therapeutic targets are required to combat multidrug resistant infections, such as the iron-regulat

95 opment and hold promise for the treatment of multidrug resistant infections.

96 eatment of several human diseases, including multidrug-resistant infections and genetic disorders.

97 nfective strategy has the potential to treat multidrug-resistant infections and limit the emergence o

98 s used in the last line of defense to combat multidrug-resistant infections by Gram-negative bacteria

99 sistance mutations shape the pathobiology of multidrug-resistant infections has the potential to driv

100 Multidrug-resistant infections were associated with rece

101 is a significant contributor to recalcitrant multidrug-resistant infections, especially in immunocomp

102 ealthcare worldwide as an important cause of multidrug-resistant infections.

103 ted bacterial pneumonia (HABP/VABP) is often multidrug-resistant infections.

104 am provides a carbapenem alternative against multidrug-resistant infections.

105 the treatment of tuberculosis, particularly multidrug-resistant infections.

106 y profiling their antiviral efficacy against multidrug-resistant influenza A viruses, in vitro drug r

107 The existence of multidrug-resistant influenza viruses, coupled with the

108 nya, and Tanzania (both sites combined), and multidrug-resistant iNTS was isolated in Burkina Faso (b

109 A clinical pathogenic multidrug-resistant isolate, E. coli 381, isolated from

110 The recent emergence of multidrug-resistant isolates has raised public health co

111 The identification of multidrug-resistant isolates highlights the need for add

112 sticity and speed of evolutionary changes in multidrug-resistant K. pneumoniae, demonstrating the hig

113 sing on the virulent, globally disseminated, multidrug-resistant lineage ST131.

114 to human cell lines, and are active against multidrug-resistant M. tuberculosis strains, indicating

115 public health efforts to limit the spread of multidrug-resistant malaria.

116 much superior to that of doxorubicin in the multidrug resistant MCF-7/ADR xenografted nude mice.

117 ests are urgently needed for the analysis of multidrug resistant (MDR) and extensively drug resistant

118 d significantly reduced drug efflux by model multidrug resistant (MDR) breast cancer cell lines (MCF-

119 ponsible for decreasing drug accumulation in multidrug resistant (MDR) cells.

120 ne in the core and pooled siRNAs that target multidrug resistant (MDR) genes in the shell.

121 ted for their antibacterial activity against multidrug resistant (MDR) Gram-positive and Gram-negativ

122 ange of therapeutic agents required to treat multidrug resistant (MDR) infections.

123 77.7% (28/36) of clinical isolates indicated multidrug resistant (MDR) patterns, 50% (18/36) indicate

124 is, resistance categories were predefined as multidrug resistant (MDR), isoniazid resistant, rifampic

125 of ceftolozane-tazobactam resistance during multidrug resistant (MDR)-Pseudomonas aeruginosa infecti

126 WHO estimates 480,000 cases of these were multidrug resistant (MDR).

127 An increase in the proportion of multidrug-resistant (MDR) 35B isolates has recently been

128 Multidrug-resistant (MDR) Acinetobacter baumannii is one

129 Multidrug-resistant (MDR) and extensively drug-resistant

130 he highest incidences of DR-TB, particularly multidrug-resistant (MDR) and extensively drug-resistant

131 Multidrug-resistant (MDR) and extensively drug-resistant

132 s are threatened by the increasing burden of multidrug-resistant (MDR) and extensively drug-resistant

133 onsumption, incidence density of Candida and multidrug-resistant (MDR) bacteria bloodstream infection

134 s known about the excess mortality caused by multidrug-resistant (MDR) bacterial infection in low- an

135 Multidrug-resistant (MDR) bacterial infections are a ser

136 Prevention of multidrug-resistant (MDR) bacterial infections relies on

137 of antibiotic resistance (AR) and spread of multidrug-resistant (MDR) bacterial pathogens.

138 re are more cases of isoniazid-resistant and multidrug-resistant (MDR) disease than are identified.

139 unctional CRISPR-Cas systems are absent from multidrug-resistant (MDR) Enterococcus faecalis, which o

140 um of activity of these antibiotics includes multidrug-resistant (MDR) gram-negative bacteria (GNB),

141 Multidrug-resistant (MDR) gram-negative bacteria have in

142 se for the treatment of infections caused by multidrug-resistant (MDR) Gram-negative bacteria.

143 Multidrug-resistant (MDR) infections are on the increase

144 in the Shigellae, particularly as a specific multidrug-resistant (MDR) lineage of Shigella sonnei (li

145 Is have been complicated by the emergence of multidrug-resistant (MDR) pathogens.

146 ntial association between TTSS genotypes and multidrug-resistant (MDR) profiles, and how this interac

147 Therapeutic interventions to treat multidrug-resistant (MDR) Pseudomonas aeruginosa infecti

148 nd die from tuberculosis (TB) each year, and multidrug-resistant (MDR) strains of TB are increasingly

149 ion model to follow a hypothetical cohort of multidrug-resistant (MDR) TB patients under different be

150 ar-negative, retreatment smear-positive, and multidrug-resistant (MDR) TB.

151 sis that were due to inadequate treatment of multidrug-resistant (MDR) tuberculosis (i.e., acquired r

152 erculosis (LTBI) after contact to infectious multidrug-resistant (MDR) tuberculosis (TB) are lacking

153 rove treatment outcomes for individuals with multidrug-resistant (MDR) tuberculosis (TB).

154 al approach to assess recent transmission of multidrug-resistant (MDR) tuberculosis and identify pote

155 The projected long-term prevalence of multidrug-resistant (MDR) tuberculosis depends upon the

156 efficacy and safety in drug-susceptible and multidrug-resistant (MDR) tuberculosis during the first

157 Globally, >30 000 children fall sick with multidrug-resistant (MDR) tuberculosis every year.

158 The transcontinental spread of multidrug-resistant (MDR) tuberculosis is poorly charact

159 A novel, shorter-course regimen for treating multidrug-resistant (MDR) tuberculosis was recently reco

160 Multidrug-resistant (MDR) tuberculosis, "Ebola with wing

161 In 31 patients with non-multidrug-resistant (MDR) tuberculosis, viability and qu

162 As treatment options for multidrug-resistant (MDR) uropathogens are limited, clin

163 g-sensitive (MIC = 0.012 muM; SI >/= 16000), multidrug-resistant (MDR), and extensively drug-resistan

164 phenicol, and trimethoprim-sulfamethoxazole (multidrug resistant [MDR]) was limited to Typhi isolates

165 otgun sequencing of all stools, we find that multidrug-resistant members of the genera Escherichia, K

166 st planktonic and biofilm forms of different multidrug resistant microorganisms, we present here the

167 a significantly increased proportion of rare multidrug-resistant molds.

168 ted complete growth inhibition in vitro of 2 multidrug-resistant MRSA strains.

169 cond-line antitubercular drug used to combat multidrug-resistant Mtb strains.

170 ts inactive variant PRD25N, and an extremely multidrug-resistant mutant, PR20.

171 osis treatments, particularly in the case of multidrug-resistant Mycobacterium tuberculosis (Mtb).

172 Treatment of multidrug-resistant Mycobacterium tuberculosis is a chal

173 Multidrug-resistant Neisseria gonorrhoeae is a top threa

174 s with Mycobacterium abscessus, a species of multidrug-resistant nontuberculous mycobacteria, are eme

175 istance in patients with drug-susceptible or multidrug-resistant (nonXDR) tuberculosis strains.

176 broad range of bacterial species, especially multidrug resistant ones.

177 compliance with prevention bundles impacted multidrug-resistant organism (MDRO) infections in Thai h

178 m difficile (OR 1.02, 95% CI 0.34-3.01), and multidrug-resistant organism (OR 1.06, 95% CI 0.42-2.71)

179 2 weeks' gestation or younger; prevalence of multidrug-resistant organism colonisation; and length of

180 Mycobacterium abscessus is a fast-growing, multidrug-resistant organism that has emerged as a clini

181 SA) is the most common healthcare-associated multidrug-resistant organism.

182 have been implicated in the transmission of multidrug-resistant organisms (MDRO).

183 The emergence and spread of multidrug-resistant organisms (MDROs) across global heal

184 Infections by multidrug-resistant organisms (MDROs) are a global threa

185 The emergence and dissemination of multidrug-resistant organisms (MDROs) is a global threat

186 bacterial infections including those due to multidrug-resistant organisms (MDROs).

187 Patients admitted to hospital can acquire multidrug-resistant organisms and Clostridium difficile

188 Multidrug-resistant organisms caused 56% of bacterial in

189 ect storm" for sustained endemicity of these multidrug-resistant organisms in Colombia.

190 h the aim to decrease selective pressure for multidrug-resistant organisms in order to preserve the u

191 strategies, may help mitigate the effect of multidrug-resistant organisms in the future.

192 day mortality, and mortality associated with multidrug-resistant organisms were significantly lower i

193 f clinical cultures that tested positive for multidrug-resistant organisms, blood culture contaminati

194 he ability of bacterial pathogens, including multidrug-resistant organisms, to colonize and subsequen

195 m were identified, including infections with multidrug-resistant organisms.

196 on therapy are common and frequently involve multidrug-resistant organisms.

197 awback, the development of infections due to multidrug-resistant organisms.

198 e therapy, neutropenia, or bacteremia due to multidrug-resistant organisms.

199 Although C auris is inherently multidrug resistant, other strains typically develop res

200 countering the emergence and transmission of multidrug-resistant P. falciparum malaria.

201 evaluated for antimalarial activity against multidrug-resistant P. yoelii in mice in the dose range

202 iparum malaria due to their activity against multidrug resistant parasites.

203 Genetic tools to detect the multidrug-resistant parasites are needed.

204 eptibility testing (AFST) of the potentially multidrug-resistant pathogen Candida glabrata against an

205 Candida auris is an emerging, often multidrug-resistant pathogen with important public healt

206 r empiric antimicrobial therapy against this multidrug-resistant pathogen.

207 n "out of the box" therapeutic treatment for multidrug resistant pathogenic bacterial infections.

208 The emerging multidrug-resistant pathogenic yeast Candida auris repre

209 s were used (P= .002), and in the absence of multidrug-resistant pathogens (P< .05).

210 We will focus on 3 important multidrug-resistant pathogens that are notoriously probl

211 However, for multidrug-resistant pathogens, demonstration of superior

212 ts with cIAI, including infections caused by multidrug-resistant pathogens.

213 ibit potent antimicrobial activities against multidrug-resistant pathogens.

214 e shown that induction of MarA can lead to a multidrug resistant phenotype at the population level.

215 ne artemisinin combination therapy (ACT) for multidrug-resistant Plasmodium falciparum malaria in Cam

216 Due to development of multidrug-resistant Plasmodium falciparum new antimalari

217 ons, antibiotic resistance, and particularly multidrug-resistant profiles, is certainly of paramount

218 Infections by multidrug-resistant Pseudomonas aeruginosa (MDRPa) are a

219 ith the adhesin MAM7 to a burn infected with multidrug-resistant Pseudomonas aeruginosa substantially

220 Falling 4C use predicted rapid declines in multidrug-resistant ribotypes R001 and R027.

221 Multidrug-resistant S Typhi was isolated in Ghana, Kenya

222 The case illustrates clinical challenges of multidrug-resistant S.

223 eus, methicillin-resistant S. aureus (MRSA), multidrug-resistant S. aureus (MDRSA), absence of scn (p

224 In areas of Asia, multidrug-resistant Salmonella enterica serovar Typhi (S

225 With the worldwide emergence of the multidrug-resistant species Candida auris, identificatio

226 Children with multidrug-resistant sporadic disease show better renal s

227 ers a novel strategy for attenuating current multidrug resistant staphylococcal infections.

228 an eight residue beta-sheet peptide) against multidrug resistant staphylococci.

229 otic resistance spreads among bacteria, with multidrug-resistant staphylococci and streptococci infec

230 h antibacterial activity against an array of multidrug-resistant staphylococci.

231 iance often leads to therapeutic failure and multidrug resistant strain development.

232 irds and, in one case, identical to a highly multidrug resistant strain isolated from a human child.

233 compounds possess potent activity against a multidrug resistant strain of P. falciparum and arrest p

234 ones, beta-lactam/beta-lactamase inhibitors, multidrug resistant strains and carbapenem-resistant Ent

235 be lethal due to the global dissemination of multidrug resistant strains.

236 The emergence of multidrug-resistant strains is an increasing danger to p

237 ns are a large proportion of HAI agents, and multidrug-resistant strains of Klebsiella pneumoniae, a

238 creasingly complicated with the emergence of multidrug-resistant strains of Mycobacterium tuberculosi

239 ed by the HIV/AIDS pandemic and emergence of multidrug-resistant strains of Mycobacterium tuberculosi

240 t in antimicrobial activity observed against multidrug-resistant strains of Pseudomonas aeruginosa an

241 multiple M. tuberculosis strains (including multidrug-resistant strains).

242 gainst Mycobacterium tuberculosis, including multidrug-resistant strains, and some species of nontube

243 its over monotherapy, it may also select for multidrug-resistant strains, particularly during long-te

244 s of function was observed exclusively among multidrug-resistant strains.

245 azole drugs, resulting in difficult-to-treat multidrug-resistant strains.

246 s steadily increased, with a predominance of multidrug-resistant strains.

247 uctions into Africa, all from Asia, involved multidrug-resistant sublineages that replaced antibiotic

248 erial specific antibiotics, and treatment of multidrug resistant TB is longer.

249 Tuberculosis (TB) and multidrug-resistant TB (MDR-TB) are major health problem

250 Multidrug-resistant TB and HIV coinfection represent sev

251 ansmission of Mtb in the largest outbreak of multidrug-resistant TB in South America to date.

252 have great potential to limit the spread of multidrug-resistant tuberculosis (MDR-TB) and extensivel

253 It is estimated that 33,000 children develop multidrug-resistant tuberculosis (MDR-TB) each year.

254 patients successfully treated for pulmonary multidrug-resistant tuberculosis (MDR-TB) in Tomsk, Russ

255 Multidrug-resistant tuberculosis (MDR-TB) is an importan

256 Less than 30% of multidrug-resistant tuberculosis (MDR-TB) patients are c

257 antibiotics recommended for the treatment of multidrug-resistant tuberculosis (MDR-TB) patients.

258 Multidrug-resistant tuberculosis (MDR-TB), caused by dru

259 e the etiology of "hotspots" of concentrated multidrug-resistant tuberculosis (MDR-tuberculosis) risk

260 focus on antibiotics that are active against multidrug-resistant tuberculosis and Gram-negative bacte

261 improve treatment outcomes for patients with multidrug-resistant tuberculosis and prevent the spread

262 Diagnosis of multidrug-resistant tuberculosis and prompt initiation o

263 WGS diagnosed a case of multidrug-resistant tuberculosis before routine diagnosi

264 ing percentage reduction in the incidence of multidrug-resistant tuberculosis by 2024 compared with c

265 system increased referrals from presumptive multidrug-resistant tuberculosis cases by >10-fold, with

266 diagnosis was completed and discovered a new multidrug-resistant tuberculosis cluster.

267 idrug-resistant tuberculosis will be primary multidrug-resistant tuberculosis compared with only 15%

268 ovements in treatment for drug-sensitive and multidrug-resistant tuberculosis could reduce the number

269 ealthcare workers with the goal of improving multidrug-resistant tuberculosis detection.

270 en has potential to substantially lessen the multidrug-resistant tuberculosis epidemic, but this effe

271 en has potential to substantially lessen the multidrug-resistant tuberculosis epidemic, but this effe

272 rge public health and societal implications, multidrug-resistant tuberculosis has been long regarded

273 ns in the primary analysis, the incidence of multidrug-resistant tuberculosis in 2024 would be 3.3 (9

274 est number of patients with tuberculosis and multidrug-resistant tuberculosis in the world.

275 of isoniazid resistance, a 152% increase in multidrug-resistant tuberculosis incidence, a 242% incre

276 rculosis, and a 275% increase in the risk of multidrug-resistant tuberculosis infection.

277 ay, 2016, WHO endorsed a 9 month regimen for multidrug-resistant tuberculosis that is cheaper and pot

278 cal agents used to halt the progression from multidrug-resistant tuberculosis to extensively resistan

279 rld Health Organization category 5 drugs for multidrug-resistant tuberculosis using a 7H9 broth micro

280 CWs in 3 district hospitals with specialized multidrug-resistant tuberculosis wards in KwaZulu-Natal,

281 By 2032, an estimated 85% of multidrug-resistant tuberculosis will be primary multidr

282 each of confirmed tuberculosis and suspected multidrug-resistant tuberculosis) to a randomly allocate

283 ence, a 242% increase in prevalent untreated multidrug-resistant tuberculosis, and a 275% increase in

284 Secondary outcomes were missed tuberculosis, multidrug-resistant tuberculosis, and comorbidities with

285 n settings with more ongoing transmission of multidrug-resistant tuberculosis, but results were other

286 d-resistant tuberculosis is more common than multidrug-resistant tuberculosis, it has been much less

287 ope is complicated by the high prevalence of multidrug-resistant tuberculosis, low rates of drug susc

288 he public sector contributed 87% of acquired multidrug-resistant tuberculosis, related to irregular a

289 h all-cause mortality among US patients with multidrug-resistant tuberculosis.

290 th a potential for immunotherapy in treating multidrug-resistant tuberculosis.

291 for the development of novel drugs to tackle multidrug-resistant tuberculosis.

292 ctinomycin antibiotic essential for treating multidrug-resistant tuberculosis.

293 terial, used in the treatment of adults with multidrug-resistant tuberculosis.

294 luating new agents/regimens for treatment of multidrug-resistant tuberculosis; and (3) evaluating saf

295 ensitive tuberculosis; improved treatment of multidrug-resistant tuberculosis; and expansion of acces

296 critical implications for drug-targeting in multidrug-resistant tumors where a stressful micro-envir

297 Broad-spectrum antibiotics for recurrent multidrug-resistant urinary tract infections (UTIs) disr

298 Concerns about multidrug-resistant uropathogens have pointed to the nee

299 tion, and only two cases of infection with a multidrug-resistant virus have been reported under adequ

300 Candida auris, a multidrug-resistant yeast that causes invasive infection